Last update 23 Jan 2025

Lanyue Biomedical Technology (Hangzhou) Co., Ltd.

Private Company|
2021|
Zhejiang Sheng, China

Overview

Tags

Congenital Disorders
Endocrinology and Metabolic Disease
Eye Diseases
AAV based gene therapy

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
AAV based gene therapy1
Top 5 TargetCount
VEGF x VEGF-A1

Related

2
Drugs associated with Lanyue Biomedical Technology (Hangzhou) Co., Ltd.
SKG-0106
Target
VEGF x VEGF-A
Mechanism
VEGF inhibitors [+2]
Active Org.
Lanyue Biomedical Technology (Hangzhou) Co., Ltd. [+2]
Originator Org.
Skyline Therapeutics (Shanghai) Co., Ltd.Skyline Therapeutics (Shanghai) Co., Ltd.
Active Indication
Wet age-related macular degeneration [+2]
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
SKG-0201
Target
SMN1
Mechanism
SMN1 modulators
Active Org.
Skyline Therapeutics (Shanghai) Co., Ltd.Skyline Therapeutics (Shanghai) Co., Ltd. [+1]
Originator Org.
Skyline Therapeutics (Shanghai) Co., Ltd.Skyline Therapeutics (Shanghai) Co., Ltd.
Active Indication
HMN (Hereditary Motor Neuropathy) Proximal Type I [+1]
Inactive Indication-
Drug Highest PhaseIND Approval
First Approval Ctry. / Loc.-
First Approval Date-
2
Clinical Trials associated with Lanyue Biomedical Technology (Hangzhou) Co., Ltd.
CTR20250009
/ Not yet recruitingNot Applicable
评价 SKG0106 用于治疗新生血管性（湿性）年龄相关性黄斑变性患者的前瞻性、非干预、多中心的长期随访研究
[Translation] A prospective, non-interventional, multicenter, long-term follow-up study evaluating SKG0106 for the treatment of patients with neovascular (wet) age-related macular degeneration
CTR20234110
/ RecruitingPhase 1/2
一项评估 SKG0106 眼内注射溶液在新生血管性年龄相关性黄斑变性（nAMD） 患者中的安全性、耐受性、疗效探索性 I/II 期临床研究
[Translation] An exploratory Phase I/II clinical study to evaluate the safety, tolerability and efficacy of SKG0106 intraocular injection solution in patients with neovascular age-related macular degeneration (nAMD)
100 Clinical Results associated with Lanyue Biomedical Technology (Hangzhou) Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Lanyue Biomedical Technology (Hangzhou) Co., Ltd.
Login to view more data
100 Deals associated with Lanyue Biomedical Technology (Hangzhou) Co., Ltd.
Login to view more data
100 Translational Medicine associated with Lanyue Biomedical Technology (Hangzhou) Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
IND Approval
1
1
Phase 2 Clinical
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
SKG-0106
 ( VEGF x VEGF-A )		Wet age-related macular degeneration
More
Phase 2 Clinical
SKG-0201
 ( SMN1 )		HMN (Hereditary Motor Neuropathy) Proximal Type I
More
IND Approval
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free